Peptides for libido and sexual health — looking beyond blood flow

In other cases, desire remains present, but the body does not respond as expected. These experiences may sound similar, but they can involve different biological, hormonal, psychological, and relational factors. Understanding those differences is essential when evaluating potential treatment options.

Sexual desire and physical function are not the same

PDE5 inhibitors, including sildenafil and tadalafil, support erectile function by increasing blood flow. These medications may be helpful when vascular function is the primary concern. However, a physical response is not the same as sexual desire.

Someone may experience improved erectile function without experiencing an increase in interest, motivation, or emotional connection. Similarly, a person may have normal physical function while experiencing a persistent reduction in desire. This distinction has encouraged clinicians and researchers to look beyond circulation and examine how the brain, hormones, emotions, medications, physical health, and relationships influence sexual well-being.

How the brain influences sexual desire

Sexual desire involves a complex interaction between the brain and body. Neural pathways associated with motivation, reward, emotional connection, stress, and hormonal signaling all contribute to how a person experiences sexual interest and arousal.

This helps explain why medications that improve blood flow may not fully address concerns involving low desire. When the underlying issue involves central nervous system signaling, hormones, emotional health, chronic stress, or relationship factors, improving circulation alone may not resolve the concern. The brain's melanocortin system is one area that has been studied in connection with sexual behavior and arousal. This system includes receptors involved in appetite, motivation, reward, and sexual response.

Bremelanotide and central sexual-response pathways

Bremelanotide is a synthetic peptide that activates melanocortin receptors in the central nervous system, particularly MC3R and MC4R. By acting on pathways in the brain rather than directly increasing genital blood flow, bremelanotide approaches sexual response differently from medications such as sildenafil and tadalafil.

Research has examined bremelanotide in premenopausal women experiencing hypoactive sexual desire disorder, commonly called HSDD. HSDD generally involves a persistent reduction in sexual desire that causes personal distress and is not better explained by another medical condition, medication, mental-health concern, or relationship issue.

Clinical studies have reported improvements in measures related to sexual desire and distress associated with low desire. However, individual responses vary, and the medication does not address every possible cause of sexual dysfunction.

Bremelanotide is generally administered by subcutaneous injection before anticipated sexual activity. Reported side effects include nausea, flushing, headache, injection-site reactions, and temporary increases in blood pressure. It may not be appropriate for individuals with certain cardiovascular conditions or uncontrolled high blood pressure.

A licensed healthcare provider must consider the patient's medical history, cardiovascular health, current medications, symptoms, and the potential cause of the sexual-health concern before determining whether treatment may be appropriate.

Hormonal health and sexual desire

Hormonal health is one of the most important components of a comprehensive sexual-health evaluation. Testosterone contributes to sexual desire in both men and women. In men, low testosterone may be associated with reduced libido, fatigue, mood changes, decreased muscle mass, and changes in erectile function.

Women also produce testosterone at lower levels, and it may contribute to sexual interest and responsiveness. Hormonal changes associated with menopause, ovarian surgery, certain medications, or endocrine conditions may influence sexual desire.

Estradiol also plays an important role. In women, reduced estradiol levels can contribute to vaginal dryness, tissue changes, discomfort during sex, and reduced physical responsiveness. When sexual activity becomes uncomfortable, desire may decline as a secondary effect.

Thyroid disorders, elevated prolactin, diabetes, and other endocrine or metabolic conditions may also contribute to changes in sexual function. For that reason, a medical evaluation may include laboratory testing based on the patient's symptoms, medical history, age, and reproductive status.

Laboratory values should not be considered in isolation. A result that falls within or outside a reference range does not independently establish the cause of a person's symptoms. Treatment decisions should reflect the complete clinical picture.

The role of sleep and stress

Sleep quality can affect energy, mood, hormonal balance, and sexual interest. Persistent sleep deprivation may contribute to fatigue and reduced emotional and physical capacity for intimacy.

Chronic stress may also interfere with sexual response. When the body remains in a prolonged stress state, attention and energy are directed toward managing perceived threats rather than supporting functions associated with rest, connection, and reproduction.

Stress may also contribute to muscle tension, difficulty concentrating, irritability, relationship conflict, and disrupted sleep. These effects can compound one another and make it difficult to identify a single cause of reduced desire.

Addressing sleep and stress does not mean that sexual-health symptoms are "all in someone's head." Both have measurable effects on physical and emotional health and should be considered legitimate parts of a medical evaluation.

Mental health and medication-related factors

Depression, anxiety, trauma, and other mental-health concerns may affect sexual desire and arousal. The symptoms of these conditions can influence energy, motivation, self-image, concentration, and emotional connection.

Some medications may also affect sexual function. Certain antidepressants, blood-pressure medications, hormonal therapies, pain medications, and other treatments may contribute to changes in libido, arousal, orgasm, lubrication, or erectile function.

Patients should not discontinue prescribed medication without speaking with their healthcare provider. A provider can evaluate whether a medication may be contributing to the symptoms and determine whether an adjustment or alternative treatment should be considered.

Physical comfort and sexual health

Pain and physical discomfort can significantly affect sexual interest. Vaginal dryness, pelvic-floor dysfunction, genitourinary symptoms of menopause, endometriosis, infections, dermatologic conditions, and other health concerns may make sexual activity uncomfortable or painful.

In men, cardiovascular disease, diabetes, neurological conditions, pelvic surgery, prostate conditions, and medication effects may contribute to changes in erectile or ejaculatory function.

When physical discomfort is present, treating the underlying cause may be more appropriate than focusing exclusively on sexual desire. A comprehensive evaluation should distinguish between reduced interest and avoidance caused by pain, fear of pain, or difficulty with physical function.

Relationship and emotional factors

Sexual health does not exist independently from a person's emotional and relational life. Relationship conflict, lack of emotional safety, communication difficulties, caregiving demands, significant life transitions, body-image concerns, and unresolved experiences surrounding sex may affect desire and arousal.

Medication cannot independently resolve every relational or emotional cause of sexual dysfunction. For some individuals or couples, counseling, sex therapy, improved communication, or other forms of support may be appropriate components of care.

Acknowledging these factors does not diminish the importance of biological treatment. Sexual-health concerns often have more than one contributing cause, and the most effective approach may involve both medical and nonmedical support.

What a sexual-health evaluation may include

A comprehensive evaluation may consider:

• The specific symptoms and when they began
• Whether the concern involves desire, arousal, physical function, pain, orgasm, or a combination of factors
• Hormonal and reproductive health
• Cardiovascular and metabolic health
• Sleep quality and fatigue
• Stress and mental health
• Current medications and supplements
• Menopause-related symptoms
• Fertility and family-planning goals
• Pain or physical discomfort
• Relationship and emotional factors

The appropriate evaluation will vary by person. Not every patient requires the same laboratory tests, treatment, or follow-up plan.

A more complete approach to sexual health

Sexual concerns may involve desire, arousal, physical function, comfort, hormonal signaling, emotional health, or several of these factors at the same time. Bremelanotide, a compounded medication, offers a centrally acting approach that differs from medications focused primarily on blood flow. However, it does not replace a comprehensive evaluation and is not appropriate for every patient.

The most effective starting point is identifying what has changed, when it changed, how the symptoms affect the individual, and which biological, psychological, medication-related, or relational factors may be contributing.

Treatment decisions should be made with a licensed healthcare provider who can evaluate the individual's symptoms, medical history, risks, laboratory findings when appropriate, and personal goals.

This article is provided for general educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Treatment availability and eligibility vary by individual and jurisdiction. A licensed healthcare provider will determine whether any treatment is medically appropriate following an evaluation. A prescription is not guaranteed.